TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04486469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy Group
Description: 1. Performing direct physical treatment on the diaphragm, using stretching, followed by teaching exercises for re-education of the abdomen and diaphragm.~2. Transcutaneous retrograde electrostimulation: L1-L4 (2hz-10hz) rectangular asymmetric biphasic at the level of the dermatome. From the anterior inferior iliac spine to a pubic symphysis. Second canal from the greater trochanter to the saphenous veins. (30 min). Parameters of this program: 2 Hz and 180ms.~3. Connective Tissue Massage or Dicke~4. Massage with direct maneuvers on the abdomen: The direction of the maneuvers will be clockwise. We will perform 6 very slow strokes adding small pressures on the ascending, transverse and descending colon respectively and repeating this maneuver 3 times. (10 minutes)
Study: NCT01122940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epamin: Reference Drug
Description: Single dose of 75 mg (10 ml in suspension) of Epamin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin: Study Drug
Description: Single dose of 75 mg (10 ml in suspension) of Phenytoin
Study: NCT04586335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYH33
Description: Clinical Activity of CYH33, an Oral α-specific PI3K Inhibitor in Combination with Olaparib, an Oral PARP Inhibitor
Study: NCT03660124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: DBS is a neurosurgical procedure that involves the administration of small amounts of electricity to disrupt abnormal activity of brain structures associated with disease symptoms. It involves inserting thin electrodes into deep brain structures and electrically stimulating them in a controllable and ultimately reversible manner. The electrodes are connected to an internal pulse generator that is implanted in the upper chest region, below the collarbone.
Study: NCT03408223

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total marrow and lymphoid irradiation
Description: Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Marrow and Lymphoid Irradiation Dose of 12-20 Gy TMLI (fraction size of 4 Gy given once a day).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0.
Study: NCT02958059

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pacetin® (cefoxitin)
Description: 1\~2g of Cefoxitin (2nd generation cephalosporin) is administered to patients 30 minutes Before ERCP procedure. Cefoxitin is mixed with 10ml of normal saline. Patients and caregivers can not distinguish antibiotics and placebo by naked eye.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10ml of normal saline is injected to patients as placebo. Patients and caregivers can not distinguish antibiotics and placebo by naked eye.
Study: NCT02200978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATO
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIF
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATRA
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mitoxantrone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone
Description: Given IV
Study: NCT04510389

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Bariatric patients with or without sarcopenia receiving maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: Bariatric patients with or without sarcopenia receiving whey protein
Study: NCT04612972

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS CoV 2 vaccine (Vero cell) Wuhan/Beijing/Placebo
Description: This clinical trial is conducted in randomized, blind, placebo controlled design Total sample size is 12 000, which are randomly allocated into investigational vaccine 1, investigational vaccine 2 and placebo control group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS CoV 2 vaccine (Vero cell) Wuhan/Beijing/Placebo
Description: This clinical trial is conducted in randomized, blind, placebo controlled design Total sample size is 12 000, which are randomly allocated into investigational vaccine 1, investigational vaccine 2 and placebo control group.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Inactivated SARS CoV 2 vaccine (Vero cell) Wuhan/Beijing/Placebo
Description: This clinical trial is conducted in randomized, blind, placebo controlled design Total sample size is 12 000, which are randomly allocated into investigational vaccine 1, investigational vaccine 2 and placebo control group.
Study: NCT03219905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Kinesio-taping
Description: The experimental group received a therapeutic Kinesio Tape application. Three I strips were applied to the both ankle joints for joint stability with subject's ankle at 90 degrees.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Kinesio-taping
Description: The control group received a sham Kinesio Tape application. Ankle position was hold at minimally plantar flexion during taping. AI strip was placed from the anterior midfoot, not stretched and attached to the midline of anterior leg.
Study: NCT04115410

Intervention type: DRUG
Intervention: PD-1 inhibitor
Description: PD-1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer. The investigators will include nivolumab, pembrolizumab, and atezolizumab as PD-1 inhibitors as these drugs are reimbursed by health authority of South Korea.

Intervention type: DRUG
Intervention: Chemotherapy Drugs, Cancer
Description: Chemotherapy is a type of pharmacotherapy for cancer, that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen. The investigators will include cytotoxic chemotherapy and tyrosine kinase inhibitors (epidermal growth cell receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors).
Study: NCT03557684

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: leucine
Description: amino acid leucine in powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: leucine
Description: amino acid leucine in powder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PO placebo
Description: maltodextrin
Study: NCT02200978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ara-C
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: Given orally
Study: NCT03557684

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PO placebo
Description: maltodextrin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lipopolysaccharide (LPS)
Description: purified bacterial wall component as an inflammatory challenge

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lipopolysaccharide (LPS)
Description: purified bacterial wall component as an inflammatory challenge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV placebo
Description: 0.9% saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV placebo
Description: 0.9% saline
Study: NCT01398410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Participants received rabeprazole 5 mg tablets and rabeprazole 10 mg matched placebo tablets orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Participants received rabeprazole 10 mg tablets and rabeprazole 5 mg matched placebo tablets orally, once daily
Study: NCT01276119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 100 mg/mL solution for injection Single infusion over 60 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 100 mg/mL solution for injection Single infusion over 120 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 100 mg/mL solution for injection Single infusion over 120 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 100 mg/mL solution for injection Single infusion over 120 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 100 mg/mL solution for injection Single infusion over 120 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 100 mg/mL solution for injection Single infusion over 120 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 100 mg/mL solution for injection Single infusion over 120 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 100 mg/mL solution for injection Single infusion over 120 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 100 mg/mL solution for injection Single sc injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 100 mg/mL solution for injection Single sc injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 100 mg/mL solution for injection Single sc injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride for injection Single infusion over 60 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride for injection Single infusion over 120 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride for injection Single sc injection
Study: NCT01656187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine 10 mg capsule
Description: Memantine oral capsule was initiated at 5 mg/day at Randomization (Week 0), then titrated to 5 mg twice a day at Week 2, then increased to 10 mg in the morning and 5 mg in the evening at Week 3, and then to 10 mg twice a day (intervention dose) at Weeks 4-24. For the participants in the Placebo, then Memantine arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine 10 mg capsule
Description: Memantine oral capsule was initiated at 5 mg/day at Randomization (Week 0), then titrated to 5 mg twice a day at Week 2, then increased to 10 mg in the morning and 5 mg in the evening at Week 3, and then to 10 mg twice a day (intervention dose) at Weeks 4-24. For the participants in the Placebo, then Memantine arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine-matched Placebo capsule
Description: Memantine-matched oral Placebo capsule was initiated at Randomization (Week 0) and maintained Weeks 0-24 in a manner consistent with the active drug titration schedule. The number of placebo capsules matched the number of active drug capsules at each titration checkpoint. For the participants in the Memantine, then Placebo arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine-matched Placebo capsule
Description: Memantine-matched oral Placebo capsule was initiated at Randomization (Week 0) and maintained Weeks 0-24 in a manner consistent with the active drug titration schedule. The number of placebo capsules matched the number of active drug capsules at each titration checkpoint. For the participants in the Memantine, then Placebo arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52).
Study: NCT01281267

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Facial Allograft Transplantation
Description: Facial allograft transplantation surgery is the transfer of face tissue from a deceased human donor to a patient with a severe facial deformity.
Study: NCT02777281

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Shoulder pain and SCI
Description: Shoulder pain and SCI

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Shoulder pain and able bodies
Study: NCT04343053

Intervention type: OTHER
Group type: OTHER
Intervention: SARS-Cov-2 infection
Description: blood sample withdrawal
Study: NCT04665518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Acupressure will be applied to the patients in the acupressure group for 10 min before the venipuncture procedure. Venipuncuture is applied to all patients by the same nurse in the same room. Venipuncture is performed from the left arm of all patients using a vacuum tube and a needle tip of 0.8 \* 38 mm (21G x 1½, green).
Study: NCT03974022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunvozertinib
Description: Daily dose of Sunvozertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunvozertinib
Description: Daily dose of Sunvozertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunvozertinib
Description: Daily dose of Sunvozertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunvozertinib
Description: Daily dose of Sunvozertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunvozertinib
Description: Daily dose of Sunvozertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunvozertinib
Description: Daily dose of Sunvozertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunvozertinib
Description: Daily dose of Sunvozertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunvozertinib
Description: Daily dose of Sunvozertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunvozertinib
Description: Daily dose of Sunvozertinib
Study: NCT04577534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iv Tocillizumab (TCZ)
Description: Participants are randomized (2:1) to receive TCZ or Standard of Care
Study: NCT02758873

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Personalised medicine (Salmeterol)
Description: If participants require add-on medication and have the Gly/Gly variant on the ADRB2, salmeterol will be prescribed.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Personalised medicine (Montelukast)
Description: If participants require add-on medication and have the Arg/Arg or Arg/Gly variant on the ADRB2, montelukast will be prescribed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: If participants require add-on medication in the arm, they will be prescribed either salmeterol or montelukast according to health professional's choice based on current guidelines.
Study: NCT00438256

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation
Description: Given over different schedules and duration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation
Description: Given over different schedules and duration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation
Description: Given over different schedules and duration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation
Description: Given over different schedules and duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given orally starting on day one of radiation therapy for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given orally starting on day one of radiation therapy for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given orally starting on day one of radiation therapy for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given orally starting on day one of radiation therapy for 2 weeks
Study: NCT03050112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MacNew questionnaire
Description: Patients will be asked to fill in the MacNew questionnaire on quality of life (phone contact).
Study: NCT00388297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Levothyroxine
Study: NCT02397460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant tablets administered orally as a single dose of 50 mg (1 tablet) or 300 mg (6 tablets)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00388297

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Levothyroxine
Study: NCT02200978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6MP
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6MP
Description: Given orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal injection
Description: Ara-C and dexamethasone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intrathecal injection
Description: Ara-C and dexamethasone
Study: NCT03328845

Intervention type: DRUG
Group type: OTHER
Intervention: Toujeo SoloStar
Description: Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.

Intervention type: DRUG
Group type: OTHER
Intervention: Toujeo SoloStar
Description: Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.
Study: NCT04012307

Intervention type: DRUG
Group type: OTHER
Intervention: Candesartan Cilexetil 32mg
Description: Candesartan Cilexetil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 32 mg of candesartan cilexetil.

Intervention type: DRUG
Group type: OTHER
Intervention: Candesartan Cilexetil 32mg
Description: Candesartan Cilexetil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 32 mg of candesartan cilexetil.

Intervention type: DRUG
Group type: OTHER
Intervention: Atacand® PROTECT
Description: Atacand® PROTECT is manufactured by AstraZeneca GmbH, Germany. Each tablet contains 32 mg of candesartan cilexetil.

Intervention type: DRUG
Group type: OTHER
Intervention: Atacand® PROTECT
Description: Atacand® PROTECT is manufactured by AstraZeneca GmbH, Germany. Each tablet contains 32 mg of candesartan cilexetil.
Study: NCT04384770

Intervention type: RADIATION
Intervention: CT-guided Stereotactic Body Radiation Therapy
Description: Undergo CT-guided SBRT

Intervention type: RADIATION
Intervention: MRI-guided Stereotactic Body Radiation Therapy
Description: Undergo MRI-guided SBRT

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03328845

Intervention type: DRUG
Group type: OTHER
Intervention: Toujeo SoloStar
Description: Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.

Intervention type: DRUG
Group type: OTHER
Intervention: Tresiba
Description: Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.

Intervention type: DRUG
Group type: OTHER
Intervention: Tresiba
Description: Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.

Intervention type: DRUG
Group type: OTHER
Intervention: Tresiba
Description: Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.

Intervention type: DRUG
Group type: OTHER
Intervention: Humalog Kwikpen
Description: Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl

Intervention type: DRUG
Group type: OTHER
Intervention: Humalog Kwikpen
Description: Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl
Study: NCT02984514

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron emission tomography with tracer 18F-deoxy glucose
Description: Assessment of activity of brown adipose tissue with positron emission tomography using the tracer 18F-deoxy glucose
Study: NCT03870529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A Compound
Description: Participants randomized to this arm will receive 7 consecutive days of of Vitamin A compound without disease progression or unacceptable toxicities. Within 21 days of completion of treatment participants will undergo surgical resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Participants randomized to this arm will receive surgical resection